Journal
ONCOTARGET
Volume 7, Issue 18, Pages 25872-25884Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.8288
Keywords
esophageal cancer; HMGA proteins; cancer progression; diagnostic marker; malignant phenotype reversion
Categories
Funding
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq - Brazil)
- Fundacao de Amparo a Pesquisa Carlos Chagas Filho (FAPERJ - Brazil)
- Swiss Bridge Foundation PNR-CNR Aging
- Associazione Italiana Ricerca sul Cancro (AIRC - Italy) [IG-11477]
- CAPES
Ask authors/readers for more resources
Esophageal Squamous Cell Carcinoma (ESCC) is the most common esophageal tumor worldwide. However, there is still a lack of deeper knowledge about biological alterations involved in ESCC development. High Mobility Group A (HMGA) protein family has been related with poor outcome and malignant cell transformation in several tumor types. In this way, the aim of this study was to analyze the expression of HMGA1 and HMGA2 expression in ESCC and their role in crucial cellular features. We evaluated HMGA1 and HMGA2 mRNA expression in 52 paired ESCC and normal surrounding tissue samples by qRT-PCR. Here, we show that HMGA2, but not HMGA1, is overexpressed in ESCC samples. This result was further confirmed by the immunohistochemical analysis. Indeed, accordingly to mRNA expression data, HMGA2, but not HMGA1, was overexpressed in approximately 90% of ESCC samples, while it was barely expressed in the respective control. Conversely, HMGA1, but not HMGA2, was overexpressed in esophageal adenocarcinoma samples. Interestingly, HMGA2 abrogation attenuated the malignant phenotype of two ESCC cell lines, suggesting that HMGA2 overexpression is involved in ESCC progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available